1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Sweden Pharmaceuticals and Healthcare Report Q2 2016

Sweden Pharmaceuticals and Healthcare Report Q2 2016

  • February 2016
  • -
  • Business Monitor International
  • -
  • 88 pages

Includes 3 FREE quarterly updates

BMI View: Sweden's epidemiological profile will continue to be attractive to manufacturers of medicinesfor non-communicable diseases. Despite the relative rapid uptake of innovative pharmaceuticals, theburden of chronic conditions will increase over the next 15 years. Presenting a challenge to drugmakers,like many other developed states, Sweden is introducing cost-containment measures to restrict thecommercial opportunities available to drugmakers.

Headline Expenditure Projections

-Pharmaceuticals: SEK39.50bn (USD4.68bn) in 2015 to SEK39.79bn (USD4.68bn) in 2016; +0.74% inlocal currency terms and -0.1% in US dollar terms.
-Healthcare: SEK371.82bn (USD44.09bn) in 2015 to SEK381.68bn (USD44.88bn) in2016; +2.7% inlocal currency terms and 1.8% in US dollar terms.

Table Of Contents

Sweden Pharmaceuticals and Healthcare Report Q2 2016
BMI Industry View 7
Table: Headline Pharmaceuticals and Healthcare Forecasts (Sweden 2014-2020) 7
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Sweden 2012-2020) 12
Healthcare Market Forecast 13
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Sweden 2012-2020) 15
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Sweden 2012-2020) 15
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Sweden 2012-2020) 15
Prescription Drug Market Forecast 16
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Sweden 2012-2020) 17
Patented Drug Market Forecast 18
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Sweden 2012-2020) 19
Generic Drug Market Forecast 20
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Sweden 2012-2020) 21
OTC Medicine Market Forecast 22
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Sweden 2012-2020) 23
Pharmaceutical Trade Forecast 24
Table: Pharmaceutical Trade Data And Forecasts (Sweden 2014-2020) 25
Table: Pharmaceutical Trade Data And Forecasts local currency (Sweden 2014-2020) 25
Industry Risk/Reward Index 26
Western Europe Risk/Reward Index 26
Sweden Risk/Reward Index 31
Rewards 31
Risks 31
Regulatory Review 33
Intellectual Property Issues 34
Pricing Regime 35
Reimbursement Regime 36
Market Overview 38
Healthcare Sector 38
Table: Healthcare Resources (Sweden 2010-2015) 41
Table: Healthcare Personnel (Sweden 2010-2015) 41
Table: Healthcare Activity (Sweden 2010-2015) 42
Research and Development 42
Table: Drug Development Member Companies of SwedenBIO, 2015 43
Clinical Trials 44
Epidemiology 45
Competitive Landscape 49
Research-Based Industry 49
Table: Multinational Market Activity 51
Pharmaceutical Distribution 52
Pharmaceutical Retail Sector 53
Company Profile 54
AstraZeneca 54
Meda 59
Medivir 63
Novartis 68
Swedish Orphan Biovitrum (SOBI) 71
Demographic Forecast 77
Table: Population Headline Indicators (Sweden 1990-2025) 78
Table: Key Population Ratios (Sweden 1990-2025) 78
Table: Urban/Rural Population and Life Expectancy (Sweden 1990-2025) 79
Table: Population By Age Group (Sweden 1990-2025) 79
Table: Population By Age Group % (Sweden 1990-2025) 80
Glossary 82
Methodology 84
Pharmaceutical Expenditure Forecast Model 84
Healthcare Expenditure Forecast Model 84
Notes On Methodology 85
Risk/Reward Index Methodology 86
Index Overview 87
Table: Pharmaceutical Risk/Reward Index Indicators 87
Indicator Weightings 88

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.